NCT05025943

Brief Summary

Elevated cholesterol, including triglyceride levels, can lead to the development of cardiovascular disease in adulthood. A diet that is rich in omega-3 fatty acids (O3FA) can improve triglyceride levels in a way that is safe and does not require medication. This is a single-center, prospective, unblinded, randomized-controlled dietary intervention study to assess the impact of an omega-3 fatty acid diet compared to a standard lifestyle intervention on serum triglyceride in patients with hypertriglyceridemia. The study consists of an 8-week dietary treatment period followed by an 8-week observation period.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
19

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 16, 2021

Completed
Same day until next milestone

Study Start

First participant enrolled

August 16, 2021

Completed
14 days until next milestone

First Posted

Study publicly available on registry

August 30, 2021

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 7, 2022

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 15, 2023

Completed
Last Updated

March 21, 2023

Status Verified

March 1, 2023

Enrollment Period

1.1 years

First QC Date

August 16, 2021

Last Update Submit

March 20, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • change in serum triglyceride level after an 8-week diet intervention compared to baseline

    The study will test whether omega-3 fatty acid enriched diet is associated with a 20% or greater reduction in serum triglyceride levels.

    8 weeks

Secondary Outcomes (1)

  • change red blood cell omega-3 fatty acid content / index after an 8-week diet intervention compared to baseline

    8 weeks

Study Arms (2)

Standard lifestyle intervention + omega-3 fatty acid enriched diet

EXPERIMENTAL

American Heart Association Target Diet/Standard Lifestyle Intervention (SLI) + omega-3 fatty acid enriched foods

Other: Diet intervention

Standard lifestyle intervention

ACTIVE COMPARATOR

American Heart Association Target Diet/Standard Lifestyle Intervention (SLI)

Other: Control group

Interventions

The intervention group will receive diet counseling and information to implement a standard lifestyle intervention plus omega-3 fatty acid enriched foods Diet assessment and counseling provided throughout study.

Also known as: Standard lifestyle intervention + omega-3 fatty acid enriched diet
Standard lifestyle intervention + omega-3 fatty acid enriched diet

The control group will receive diet counseling and information to implement a standard lifestyle intervention Diet assessment and counseling provided throughout study.

Also known as: Standard lifestyle intervention
Standard lifestyle intervention

Eligibility Criteria

Age10 Years - 17 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Male or female patients who are 10 -17 years of age
  • BMI greater than or equal to the 85th percentile
  • Clinical serum triglyceride level \>150 mg/dl and \< 500 mg/dl performed between 3 months and 1 week prior to study visit 1
  • Ability to follow the study procedures and adhere to the diet counseling recommendations
  • Written parental permission and assent are obtained prior to any research procedures

You may not qualify if:

  • Type 2 DM (hemoglobin A1C \>6.6%)
  • Isotretinoin use
  • Chronic kidney disease (CKD)
  • Uncontrolled hypothyroidism
  • Warfarin use
  • Liver disease (NAFLD is allowed)
  • Renal disease
  • Corticosteroid use
  • Omega-3 fatty acid use (prescription or supplement)
  • Allergy to fish and/or nuts
  • Currently pregnant or planning to become pregnant during the course of this trial - confirmed by date of LMP/querying family
  • Any significant medical condition which the investigator believes would interfere with participation in this study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nemours Cardiac Center, Nemours Children's Hospital Delaware

Wilmington, Delaware, 19803, United States

Location

MeSH Terms

Conditions

Hypertriglyceridemia

Interventions

Control Groups

Condition Hierarchy (Ancestors)

HyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Epidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethods

Study Officials

  • Carissa Baker-Smith, MD, MPH, MS

    Nemours Cardiac Center, Nemours Children's Hospital Delaware

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 16, 2021

First Posted

August 30, 2021

Study Start

August 16, 2021

Primary Completion

September 7, 2022

Study Completion

March 15, 2023

Last Updated

March 21, 2023

Record last verified: 2023-03

Data Sharing

IPD Sharing
Will not share

Locations